Akershus University Hospital is a Norwegian public university hospital in the Greater Oslo Region. It is located in the Lørenskog municipality in the region of Viken, northeast of the Norwegian capital Oslo.

There are 953 beds in Akershus universitetssykehus HF; Nevroklinikken S203.

During the past decade, Akershus universitetssykehus HF; Nevroklinikken S203 conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Akershus universitetssykehus HF; Nevroklinikken S203" are "Alzheimer's Disease" (1 trials) and "Multiple Sclerosis, Relapsing-Remitting" (1 trials). Many other conditions were trialed in "Akershus universitetssykehus HF; Nevroklinikken S203" in a lesser frequency.

Most popular intervention types in "Akershus universitetssykehus HF; Nevroklinikken S203" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Crenezumab" (1 trials), "Ocrelizumab" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Akershus universitetssykehus HF; Nevroklinikken S203" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Akershus universitetssykehus HF; Nevroklinikken S203". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Akershus universitetssykehus HF; Nevroklinikken S203, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Akershus universitetssykehus HF; Nevroklinikken S203, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".